Answers are grounded in this paper and cite their sources.
Aims and background: Abnormal uterine bleeding (AUB) affects approximately 33% of Indian women.Managing AUB types poses challenges, but norethisterone acetate (NETA) controlled release (CR) holds potential in addressing it.We assessed NETA-CR utilization for AUB management in Indian clinical settings.Materials and methods: This real-world, cross-sectional, observational study analyzed 784 patients from 387 centers.Primary endpoints included change in bleeding days, endometrial thickness, and hemoglobin (Hb) levels; secondary endpoints comprised prevalent types of AUB based on PALM-COEIN classification and safety assessments.Study was conducted in compliance with the ethical standards outlined in the Declaration of Helsinki and the International Conference on Harmonization (ICH) good clinical practice guidelines (GCP).Results: Per protocol analysis, n = 784 participants with age 33.81 ± 8.45 years, weight 60.39 ± 9.16 kg, and Hb 9.31 ± 1.31 gm/dL were included.Symptoms included menorrhagia (80.99%), painful cramps 39.80% (n = 312), pelvic pain 34.18% (n = 268), blood clots 32.91% (n = 258), and backache 21.05% (n = 165).Comorbidities included polycystic ovarian syndrome (n = 326, 41.58%) and PID (n = 141, 17.98%).The NETA-CR was started at a 10 mg dose in 62.12% (n = 487) of patients, which increased to 82.27% (n = 645) at week 8. Concomitant medication included tranexamic acid (n = 242, 30.87%).Significant reductions were observed in bleeding days by 3.56 days (32.40%, p < 0.0001) and endometrial thickness by 2.01 mm (9.10%, p < 0.0001), with improvements in Hb by 1.01 gm/dL (11.88%, p < 0.0001) at week 8.The most prevalent AUB types were AUB-A 35.08% (n = 275), AUB-O 23.60% (n = 186), and AUB-E 16.45% (n = 129).Adverse drug reactions were bloating and altered taste reported in only 0.13% (n = 1) of patients each.Conclusion: The study underscores the potential of NETA-CR in managing AUB in high-risk women with adenomyosis and ovulatory dysfunction, reducing bleeding days and correcting Hb and endometrial functioning.Clinical significance: The NETA-CR helps to improve Hb irrespective of iron supplementation and AUB types.About 61.4% women had <7 bleeding days; 38.6% experienced ≥7 bleeding days.
No takes yet. Share an insight, caveat, or question.
Munshi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: